Skip to content
  • CONTACT US
  • CAREERS
  • Share
Allogene Logo
  • ABOUT US
    • AT A GLANCE
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • SCIENTIFIC ADVISORS
    • PARTNERS
  • AlloCAR T™
    • HISTORY OF CAR T
    • NEXT REVOLUTION IN CELL THERAPY
    • PLATFORM FOR TOMORROW
    • ON-DEMAND AVAILABILITY
  • PIPELINE
    • AlloCAR T™ PIPELINE
    • DATABRIEF
    • CLINICAL TRIALS
    • EXPANDED ACCESS
    • SCIENTIFIC PUBLICATIONS
  • OUR CULTURE
    • ESG REPORT
    • WE ARE ONE ALLOGENE
    • REVOLUTIONIZING CELL THERAPY
    • DIVERSITY, EQUITY, INCLUSION AND BELONGING
    • JOIN THE ALLOGENE COMMUNITY
  • NEWS CENTER
    • PRESS RELEASES
    • EVENTS
    • PERSPECTIVES
    • OUR TWEETS
    • COMMUNITY GUIDELINES
  • INVESTORS
    • IR OVERVIEW
    • NEWS & EVENTS
      • PRESS RELEASES
      • EVENTS
      • PRESENTATIONS
    • STOCK INFORMATION
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
      • INVESTMENT CALCULATOR
    • CORPORATE GOVERNANCE
      • DOCUMENTS & CHARTERS
      • ESG REPORT
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIALS & FILINGS
      • SEC FILINGS
    • RESOURCES
      • INVESTOR FAQs
      • EMAIL ALERTS
      • IR INQUIRY
  • ABOUT US
    • AT A GLANCE
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • SCIENTIFIC ADVISORS
    • PARTNERS
  • AlloCAR T™
    • HISTORY OF CAR T
    • NEXT REVOLUTION IN CELL THERAPY
    • PLATFORM FOR TOMORROW
    • ON-DEMAND AVAILABILITY
  • PIPELINE
    • AlloCAR T™ PIPELINE
    • DATABRIEF
    • CLINICAL TRIALS
    • EXPANDED ACCESS
    • SCIENTIFIC PUBLICATIONS
  • OUR CULTURE
    • ESG REPORT
    • WE ARE ONE ALLOGENE
    • REVOLUTIONIZING CELL THERAPY
    • DIVERSITY, EQUITY, INCLUSION AND BELONGING
    • JOIN THE ALLOGENE COMMUNITY
  • NEWS CENTER
    • PRESS RELEASES
    • EVENTS
    • PERSPECTIVES
    • OUR TWEETS
    • COMMUNITY GUIDELINES
  • INVESTORS
    • IR OVERVIEW
    • NEWS & EVENTS
      • PRESS RELEASES
      • EVENTS
      • PRESENTATIONS
    • STOCK INFORMATION
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
      • INVESTMENT CALCULATOR
    • CORPORATE GOVERNANCE
      • DOCUMENTS & CHARTERS
      • ESG REPORT
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIALS & FILINGS
      • SEC FILINGS
    • RESOURCES
      • INVESTOR FAQs
      • EMAIL ALERTS
      • IR INQUIRY
Read more about the article Constitutive Turbodomains Enhance Expansion and Antitumor Activity of Allogeneic BCMA CAR T Cells in Preclinical Models

Constitutive Turbodomains Enhance Expansion and Antitumor Activity of Allogeneic BCMA CAR T Cells in Preclinical Models

  • Post author:andrewkaretas
  • Post published:August 23, 2023
  • Post category:BCMA/Scientific Publications

Continue ReadingConstitutive Turbodomains Enhance Expansion and Antitumor Activity of Allogeneic BCMA CAR T Cells in Preclinical Models
Read more about the article Allogeneic BCMA-Targeting CAR T Cells in Relapsed/Refractory Multiple Myeloma: Phase 1 UNIVERSAL Trial Interim Results

Allogeneic BCMA-Targeting CAR T Cells in Relapsed/Refractory Multiple Myeloma: Phase 1 UNIVERSAL Trial Interim Results

  • Post author:andrewkaretas
  • Post published:January 18, 2023
  • Post category:BCMA/Scientific Publications

Continue ReadingAllogeneic BCMA-Targeting CAR T Cells in Relapsed/Refractory Multiple Myeloma: Phase 1 UNIVERSAL Trial Interim Results
Read more about the article Poster, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Poster, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

  • Post author:andrewkaretas
  • Post published:December 18, 2022
  • Post category:BCMA/Scientific Publications

Continue ReadingPoster, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Read more about the article Presentation, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Presentation, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

  • Post author:andrewkaretas
  • Post published:December 7, 2022
  • Post category:BCMA/Scientific Publications

Continue ReadingPresentation, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Read more about the article Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors

Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors

  • Post author:andrewkaretas
  • Post published:March 18, 2022
  • Post category:BCMA/Scientific Publications

Continue ReadingAllogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
Read more about the article UNIVERSAL Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

UNIVERSAL Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

  • Post author:andrewkaretas
  • Post published:December 18, 2021
  • Post category:BCMA/Scientific Publications

Continue ReadingUNIVERSAL Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Read more about the article Preclinical Evaluation of ALLO-605, an Allogeneic BCMA TurboCAR T™ Cell Therapy for the Treatment of Multiple Myeloma

Preclinical Evaluation of ALLO-605, an Allogeneic BCMA TurboCAR T™ Cell Therapy for the Treatment of Multiple Myeloma

  • Post author:andrewkaretas
  • Post published:December 22, 2020
  • Post category:BCMA/Scientific Publications

Continue ReadingPreclinical Evaluation of ALLO-605, an Allogeneic BCMA TurboCAR T™ Cell Therapy for the Treatment of Multiple Myeloma
Read more about the article First-in-Human Study of the Allogeneic Anti-BCMA ALLO-715 CAR T cell Therapy and the Anti-CD52 Mab ALLO-647 in Relapsed/Refractory Multiple Myeloma (UNIVERSAL Study)

First-in-Human Study of the Allogeneic Anti-BCMA ALLO-715 CAR T cell Therapy and the Anti-CD52 Mab ALLO-647 in Relapsed/Refractory Multiple Myeloma (UNIVERSAL Study)

  • Post author:andrewkaretas
  • Post published:December 9, 2020
  • Post category:BCMA/Scientific Publications

Continue ReadingFirst-in-Human Study of the Allogeneic Anti-BCMA ALLO-715 CAR T cell Therapy and the Anti-CD52 Mab ALLO-647 in Relapsed/Refractory Multiple Myeloma (UNIVERSAL Study)
Read more about the article American Society of Hematology (ASH) Dec. 2019 – Allogeneic Anti-BCMA CAR T Cells Show Tumor Specific Killing Against Primary Multiple Myeloma Cells

American Society of Hematology (ASH) Dec. 2019 – Allogeneic Anti-BCMA CAR T Cells Show Tumor Specific Killing Against Primary Multiple Myeloma Cells

  • Post author:andrewkaretas
  • Post published:December 18, 2019
  • Post category:BCMA/Scientific Publications

Continue ReadingAmerican Society of Hematology (ASH) Dec. 2019 – Allogeneic Anti-BCMA CAR T Cells Show Tumor Specific Killing Against Primary Multiple Myeloma Cells

Recent Posts

  • Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
  • September 26, 2023 11:00 AM EDT : Jefferies Cell & Genetic Medicine Summit
  • September 26, 2023 – September 27, 2023 : Jefferies Cell & Genetic Medicine Summit
  • September 12, 2023 3:45 PM EDT : Baird 2023 Global Healthcare Conference
  • Allogene Therapeutics Announces Participation in September Investor Conference

Recent Comments

No comments to show.
Allogene

CONNECT

210 E. Grand Avenue
South San Francisco, CA 94080

View Map / Contact Us

LinkedIn
Twitter
  • ABOUT US
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
  • AlloCAR T™
    • History of CAR T
    • Next Revolution in Cell Therapy
    • Platform for Tomorrow
    • On-Demand Availability
  • PIPELINE
    • AlloCAR T™ Pipeline
    • DATABRIEF
    • Clinical Trials
    • Expanded Access
    • Scientific Publications
  • OUR CULTURE
    • ESG Report
    • We Are One Allogene
    • Revolutionizing Cell Therapy
    • Diversity, Equity, Inclusion and Belonging
    • Join the Allogene Community
  • NEWS CENTER
    • Press Releases
    • Events
    • Perspectives
    • Our Tweets
    • Community Guidelines
  • INVESTORS
    • Press Releases
    • Events
    • Presentations
    • Stock Information
    • Historic Price Lookup
    • Investment Calculator
    • Corporate Governance
    • Committee Composition
    • SEC Filings
    • Resources/FAQs
    • Email Alerts
    • Investor Contacts
Facebook
Twitter
LinkedIn
E-Mail
Tumblr
Reddit
WhatsApp
Telegram
Allogene

CONNECT

210 E. Grand Avenue
South San Francisco, CA 94080

View Map / Contact Us

LinkedIn
Twitter
  • ABOUT US
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
  • AlloCAR T™
    • History of CAR T
    • Next Revolution in Cell Therapy
    • Platform for Tomorrow
    • On-Demand Availability
  • PIPELINE
    • AlloCAR T™ Pipeline
    • DATABRIEF
    • Clinical Trials
    • Expanded Access
    • Scientific Publications
  • OUR CULTURE
    • ESG Report
    • We Are One Allogene
    • Revolutionizing Cell Therapy
    • Diversity, Equity, Inclusion and Belonging
    • Join the Allogene Community
  • NEWS CENTER
    • Press Releases
    • Events
    • Perspectives
    • Our Tweets
    • Community Guidelines
  • INVESTORS
    • Press Releases
    • Events
    • Presentations
    • Stock Information
    • Historic Price Lookup
    • Investment Calculator
    • Corporate Governance
    • Committee Composition
    • SEC Filings
    • Resources/FAQs
    • Email Alerts
    • Investor Contacts

©2022 ALLOGENE THERAPEUTICS

TERMS OF USE

COOKIE SETTINGS

PRIVACY NOTICE

©2022 ALLOGENE THERAPEUTICS

TERMS OF USE

COOKIE SETTINGS

PRIVACY NOTICE